AGER
Advanced glycation end product-specific receptor
As of the edition of 20 October 2026, AGER (advanced glycation end product-specific receptor, UniProt Q15109) has 1 drug tested at it and 3 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15109
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 34
- Disease areas
- Cancer; Nervous system; Mental health; Digestive system; Hormones; Infections; Lungs and airways; Pregnancy and women's health
- Registered trials of its drugs
- 16
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Azeliragon | Stopped | Phase 3 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Cantex Pharmaceuticals | Route A |
| vTv Therapeutics | Route A |
The other 1 company at AGER
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at AGER, ranked, with the facts behind eachRequest access. Nothing is shown until you do.